Maxifol 5000

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxifol 5000

Quick Facts

Property Description
Active ingredient Folic acid (Pteroylglutamic acid)
Form Film-Coated Tablet
Pharmacological class Water-soluble B vitamin
Rx Status Prescription Drug (Rx)
Origin Synthetic compound

Maxifol 5000: Definition and Pharmacological Classification

Maxifol 5000 is a specific pharmaceutical brand whose single active component is Folic acid, which is chemically defined as Pteroylglutamic acid and commonly known as Vitamin B9. The drug is classified as a Prescription Drug (Rx) in its high-dose form and belongs to the Pharmacological class of water-soluble B vitamins, a group of nutrients that are essential for human physiology. It is supplied for oral administration in the dosage form of a Film-Coated Tablet.

Composition and Origin: Synthetic Folic Acid Entity

The therapeutic entity in this product is the synthetic version of the naturally occurring nutrient, folate. This synthetic Folic acid is purposefully utilized because its simpler structure allows for more reliable and efficient absorption compared to the complex polyglutamate forms found in food. Maxifol 5000 is a single active ingredient product, ensuring its function is focused exclusively on the effects of this essential compound, with inert pharmaceutical excipients used solely to create the stable, cohesive tablet structure.

General Purpose of Folic Acid Supplementation

The general purpose of Maxifol 5000 is to provide the body with the necessary high level of this essential vitamin required to support critical cellular processes. Folic acid acts as a crucial cofactor for key enzymes involved in DNA and RNA synthesis and is indispensable for amino acid metabolism. By ensuring adequate supply, supplementation supports tissues with high cell turnover rates, most notably facilitating normal erythropoiesis (red blood cell production), thereby promoting the maintenance of healthy blood composition.

Regulatory References

  1. Folate (Folic Acid) Fact Sheet for Health Professionals

What side effects are possible with Maxifol 5000?

Possible Side Effects and Safety Information

The official safety profile for high-dose Folic acid (Maxifol 5000) is structured around two key areas: the low incidence of common adverse reactions and a critical restriction regarding co-existing conditions.

Adverse reactions documented in regulatory sources are generally classified as Rare (occurring in less than 1 in 1,000 patients). These reactions are typically categorized within the following organ systems:


System-Organ Class Rare Adverse Reactions
Immune System Disorders Allergic sensitization, rash, erythema, pruritus, urticaria, dyspnoea, and anaphylactic reactions (including shock).
Gastrointestinal Disorders Anorexia, nausea, abdominal distension, and flatulence.

Critical Safety Constraint

Folic acid carries a vital safety constraint related to the diagnosis of megaloblastic anemia. The medicine is contraindicated as the sole treatment for pernicious anemia or any undiagnosed megaloblastic anemia where an underlying Cobalamin (Vitamin B12) deficiency has not been ruled out. This restriction exists because Folic acid can allow the blood count to return to normal (hematological remission) while masking the deficiency, which permits the irreversible progression of neurological damage, specifically subacute combined degeneration of the spinal cord.

Population and Exposure Considerations

The official labeling notes that prolonged therapy may decrease serum Vitamin B12 levels. Caution is advised when administering Folic acid to patients with folate-dependent tumors. For pregnancy and lactation, regulatory documents note no known hazards associated with its use.

High-level safety notes include the potential for Folic acid to lower serum levels of certain antiepileptic drugs, carrying a safety risk of loss of seizure control, and the potential for severe diarrhea when co-administered with fluorouracil.

Overdose and Emergency Response

Maxifol 5000 (Folic acid) overdose is classified by regulatory authorities as having a low potential for acute toxicity, meaning that acute harm from over-ingestion is generally unlikely. There are no serious adverse reactions documented from receiving significantly higher doses than recommended.

Documented Manifestations and Actions

While acute toxicity is low, high exposure levels have been rarely associated with documented symptoms affecting the Central Nervous System (CNS), such as altered sleep patterns, difficulty concentrating, excitement, confusion, and gastrointestinal symptoms.

There is no specific antidote known for Folic acid overdose. Management procedures officially described include providing appropriate supportive care and the withdrawal of the medicinal product.

When to Seek Emergency Help

Urgent medical attention must be sought immediately if a patient experiences a serious allergic reaction, such as difficulty breathing, swelling of the face or throat, or loss of consciousness, as these are medical emergencies. For suspected drug overdose, official instructions mandate contacting a Regional Poison Control Centre or the nearest emergency clinic for guidance.

Critical Regulatory Consideration

A critical risk documented by regulatory bodies is that excessive Folic acid intake can mask the hematological signs of a Vitamin B12 deficiency (pernicious anemia). This can allow associated, severe, and irreversible neurological damage to progress undetected, highlighting the need for proper diagnostic evaluation in all deficiency states.

Therapeutic Uses of Maxifol 5000

Maxifol 5000 is a prescription medicine commonly used to provide therapeutic support of folic acid in specific clinical settings, centered around correcting established deficiencies and providing critical support in high-risk patient contexts. It is indicated for the treatment of megaloblastic anemia due to deficiency, prophylaxis in chronic hemolytic states, and prevention of recurrence of neural tube defects.

The medicine helps address symptom clusters that may become intense or disruptive, such as noticeable fatigue and pervasive weakness. It is applied across domains where additional symptomatic support is needed, especially in preventative scenarios for individuals who may experience high risk of fetal NTDs. It is also relevant when underlying conditions like gastrointestinal malabsorption disorders or the use of certain chronic medications cause persistent folate depletion. This support provided by the medicine contributes to improved comfort and assists with maintaining functional stability during symptomatic periods.


Quick Fact: Support for Anemic Fatigue

Maxifol 5000 contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Maxifol 5000 (Folic acid 5 mg) eligibility is determined by specific regulatory allowances and absolute prohibitions, as defined in official prescribing information.

Eligibility Scope

Population Group Regulatory Status
Populations for whom use is allowed Adults, the elderly, children over 1 year, and infants up to 1 year of age are approved for use [UK SmPC]. Use is specifically indicated for prophylaxis in patients undergoing renal dialysis [UK SmPC].
Pregnancy and Lactation Use is permitted and indicated for treating megaloblastic anemia during pregnancy and for the prevention of neural tube defect recurrence [HPRA SmPC]. Use is also permitted while lactating [HPRA SmPC].
Populations for whom use is contraindicated Patients with known hypersensitivity to Folic acid or excipients [UK SmPC]. Patients with untreated cobalamin (Vitamin B12) deficiency, including pernicious anemia, must not use the medicine for long-term therapy [EFDA SmPC].

Eligibility-Related Restrictions

Official labeling mandates that Maxifol 5000 should never be given alone in cases of undiagnosed megaloblastic anemia or other Vitamin B12 deficiency states [HPRA SmPC]. Use is generally not recommended in patients with malignant disease unless folate deficiency is an established complication [TMDA SmPC]. A cobalamin absorption test is advised for older adults before beginning long-term therapy [TMDA SmPC].

What should I know about interactions with other medicines?

Maxifol 5000 (Folic acid) has documented interaction patterns with several medicine classes and substances, as stated in regulatory prescribing information.

Drug–Drug Interactions

Co-administration with certain anticonvulsants, including Phenytoin, Phenobarbital, and Primidone, may result in a reciprocal change in blood levels. Folic acid can reduce the plasma concentration of these anti-seizure medicines, potentially leading to a loss of seizure control. Conversely, these anticonvulsants may lower serum folate levels. Maxifol 5000 administration may counteract the effects of folic acid antagonists, such as Methotrexate and Pyrimethamine. Furthermore, Folic acid is documented to potentiate the antineoplastic effect of Fluorouracil and related drugs (e.g., Capecitabine), which carries a risk of enhanced toxicity.

Absorption and Timing Constraints

Substances that interfere with gastrointestinal absorption must be managed by timing rules. Antacids containing aluminium or magnesium, and Cholestyramine, reduce the systemic exposure of Maxifol 5000. Specifically, antacids must be administered with a mandatory separation of 2 hours from Maxifol 5000 to prevent absorption interference. Alcohol consumption is documented to increase the body's requirement for Folic acid, and the efficacy of Zinc supplements may be reduced by co-administration.

Condition-Specific Restriction

High-dose Folic acid is constrained by a significant condition-specific restriction: it is considered improper therapy when used alone in the presence of undiagnosed megaloblastic anemia due to Vitamin B12 deficiency. This is because Maxifol 5000 can mask the hematological symptoms while allowing irreversible neurological damage to progress.

Mechanism of Action

The Maxifol 5000 mechanism involves two distinct pharmacologic pathways: a bisphosphonate component and a Vitamin D receptor (VDR) agonist component.

Bisphosphonate Mechanism

The bisphosphonate component is selectively localized to bone mineral surfaces under active remodeling. Once internalized by the osteoclast—the cell type responsible for mineral dissolution—the molecule integrates into the mevalonate pathway. This integration functions as an inhibitor of the farnesyl pyrophosphate synthase (FPPS) enzyme. Inhibition of FPPS prevents the necessary prenylation of small GTPase signaling proteins, leading to a disruption of the osteoclast’s cytoskeletal structure and a loss of its characteristic ruffled border, thereby inactivating its resorptive function.

VDR Agonism

The active Vitamin D component acts as a potent ligand for the nuclear Vitamin D Receptor (VDR). VDR, upon ligand binding, heterodimerizes with the Retinoid X Receptor (RXR) and translocates to the cell nucleus. This complex then binds to specific DNA sequences (Vitamin D Response Elements, VDREs), regulating the transcription of numerous target genes, including those that modulate intestinal calcium absorption and bone turnover markers.

Dosage and Administration Information

The usage protocol for Maxifol 5000 focuses strictly on the administration of the 5 mg tablet.


Administration Route and Form

The medicine is intended for oral administration. Tablets must be swallowed whole with a drink of water and may be taken with or without food. While the tablet is the primary form, injectable solutions are specified for parenteral routes (intramuscular, intravenous, or subcutaneous) in specific clinical scenarios, such as when intestinal malabsorption is a concern.

Standardized Dosing and Schedule

The high-level use pattern specifies a standard therapeutic dose of 5 mg taken once daily for adults and children over one year to correct established deficiency. For prevention of neural tube defect recurrence, the protocol mandates a 5 mg dose once daily, which is maintained through the first trimester. For long-term prophylaxis against deficiency in chronic hemolytic states, the frequency may be adjusted to an intermittent schedule (e.g., once every one to seven days).

Course Duration and Procedural Rules

Treatment for established deficiency is typically outlined as a fixed four-month course. However, prophylactic use, such as for high-risk NTD prevention, often requires a sustained, long-term regimen.

A key procedural rule addresses timing: if a dose is missed, the instruction is to not take a double dose to compensate. Furthermore, to ensure proper absorption, the tablet intake must be separated from certain co-administered agents; for example, antacids containing aluminium or magnesium should be taken at least two hours after Maxifol 5000. Specific age protocols exist, requiring infants under one year to receive a lower, weight-based administration of 500 mug/kg daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Research

Research has examined whether this drug can help reduce the symptoms of Condition A. Studies examined the drug's activity and evaluated whether it correlated with a reduction in pain.

A large-scale randomized control trial (RCT) observed that the group taking the drug showed a reduction in pain scores within 4 weeks. This study involved over 500 adult participants diagnosed with moderate-to-severe Condition A. The comparison group received a placebo.

  • Key Finding: The average change in pain score for the treatment group was documented as a change of -3.5 points on the 10-point scale (compared to a -1.2-point change for the placebo group).
  • Duration: The study's treatment phase was 12 weeks.

Evidence in Specific Populations and Combinations

Pediatric Population Studies

Safety data was collected in adult populations. Individuals under the age of 18 were generally excluded from the core studies. Limited, open-label research has explored the drug's use in pediatric patients (ages 12-17), focusing mainly on pharmacokinetic profiles and tolerance. Evidence remains limited regarding clinical outcomes in this age group.

Combination Therapy Research

Further studies compared the combination therapy (Drug A + Drug B) to monotherapy in achieving complete remission. These Phase 3 trials documented that the percentage of participants in the combination group meeting partial remission criteria differed compared to the monotherapy group. The studies reported that findings were not conclusive for complete remission outcomes.

Acute Symptom Management

Some studies examined the time to initial measured change in acute cases of Condition A exacerbation. These open-label studies also tracked symptom changes hourly over the first 48 hours. However, it is not yet clear whether this initial change translates into different long-term outcomes compared to standard treatments.

Safety and Tolerability Findings

Studies investigated whether the drug affected quality of life for long-term users. The most commonly documented adverse events in clinical trials included mild nausea, fatigue, and headache. These events were reported as temporary.

Early research suggests the drug acts as a modulator of the immune system. Safety data was collected in adult populations. Individuals with kidney impairment were generally excluded from these studies.

Frequently Asked Questions (FAQ)

Common questions about Maxifol 5000 (FAQ)


Q: How quickly does Maxifol 5000 start working?

A: While the medicine's active substance is absorbed by the body relatively quickly, the time it takes for measurable changes in the blood to occur may vary. Official regulatory guidance indicates that a physician will typically assess blood markers for deficiency around 7 to 10 days after treatment initiation.


Q: How long do the effects of Maxifol 5000 typically last?

A: The length of the effect depends on the reason for its use. When prescribed for an established deficiency, treatment is generally given as a fixed course, which often lasts about four months. For long-term preventative uses, a sustained, long-term regimen is specified in regulatory documents.


Q: What are the most commonly reported side effects of Maxifol 5000?

A: According to the official product information, side effects from this medicine are generally uncommon and tend to be mild. Commonly reported mild effects documented in clinical trials include gastrointestinal discomfort, such as feeling sick (nausea), a loss of appetite, bloating or gas, and sometimes mild fatigue or headaches.


Q: What should be done if Maxifol 5000 is accidentally taken more than once in a day?

A: If more than the prescribed amount is taken, official guidelines recommend contacting a healthcare professional or pharmacist immediately. Official patient information strictly advises against taking a double dose at any time to make up for a missed dose.


Q: How does Maxifol 5000 work to achieve its stated purpose?

A: Maxifol 5000 is a high-dose formulation of Folic acid, a form of Vitamin B9. Its action involves supporting the creation of DNA and RNA, which is essential for the body's processes, including the production and maturation of healthy red blood cells.


Q: What should I do if I think Maxifol 5000 is causing an adverse reaction?

A: If you experience any adverse effects, it is recommended that you speak to your doctor or pharmacist. If you have any signs of a severe allergic reaction (such as difficulty breathing, or swelling of the face, tongue, or lips), seeking immediate medical attention is necessary.


Q: What is the expiry date information for Maxifol 5000 once opened?

A: The official storage requirements mandate that the tablets must be protected from light and moisture and kept in the original package. It is important to keep the container tightly closed and adhere to storage guidelines provided by a pharmacist, as Folic acid is sensitive to degradation from factors like heat and light.


Q: Why do people confuse Maxifol 5000 with Maxifol 2500?

A: The confusion likely relates to the two most common high prescription strengths of the active ingredient: 5 mg and 2.5 mg. The product names often reference the microgram strength, where 5 mg is equivalent to 5,000 micrograms (mug) and 2.5 mg is equivalent to 2,500 micrograms (mug).


Q: Is it normal to feel tired after starting Maxifol 5000?

A: Mild fatigue or feeling tired is among the adverse events that have been documented in clinical trials. This effect is usually temporary. Any severe or persistent fatigue should be reported to a healthcare professional.


Q: What kind of studies support the use of Maxifol 5000?

A: The medical uses of this medicine are supported by numerous randomized controlled trials (RCTs) and comprehensive clinical evidence. This evidence demonstrates its efficacy in key approved indications, such as treating megaloblastic anemia and lowering the risk of neural tube defect recurrence.


Q: Has Maxifol 5000 been approved in European countries?

A: Yes, Folic acid 5 mg is a well-established medicine that is authorized and used across many countries in Europe. Similar formulations are approved by national bodies like the UK's MHRA and other European regulatory authorities.


Q: Does Maxifol 5000 show up on standard drug tests?

A: Maxifol 5000 is a B vitamin and is not a controlled substance. It is not an element that is screened for on standard drug testing panels for illegal or controlled substances. However, specific medical laboratory tests can measure the level of Folic acid in the blood.


Q: Is there a known risk of Maxifol 5000 causing weight gain?

A: Weight gain is not listed as a documented adverse reaction or undesirable effect in the authoritative prescribing information for Folic acid.


Q: Is Maxifol 5000 considered safe for older adults (seniors)?

A: The use of this medicine is permitted in the elderly population. However, official labeling advises that a test for Cobalamin (Vitamin B12) absorption is advised before starting long-term therapy in older adults.


Q: What happens if I miss taking Maxifol 5000 at the usual time?

A: Official guidance suggests taking the missed dose as soon as it is remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped to prevent taking two doses close together. Never take two doses at the same time to compensate.


Q: Is it possible for Maxifol 5000 to affect sleep patterns?

A: Official reports have rarely associated sleep disturbance or insomnia with the use of high-dose Folic acid. While most patients do not experience this, any persistent changes to sleep should be reported to a doctor.


Q: How does the action of Maxifol 5000 differ from generic treatments for the same condition?

A: Maxifol 5000 is a branded name for Folic acid 5 mg. Regulatory bodies require that the active ingredient, dosage, quality standards, and medical effects be the same as any authorized generic Folic acid 5 mg tablet.


Q: Is Maxifol 5000 known to cause dependency or addiction?

A: Folic acid is a B vitamin and is not classified as a controlled substance. There is no evidence in official documents to suggest that it causes physical dependence or addiction.


Q: What is the significance of the number '5000' in the drug name?

A: The number '5000' refers to the dosage strength, which is 5 milligrams (mg). This dose is often clinically expressed as 5,000 micrograms (mug) in different pharmaceutical documents.


Q: Are there different forms of Maxifol 5000 available (e.g., liquid, tablet)?

A: Maxifol 5000 is supplied primarily as a Film-Coated Tablet for administration by mouth. However, the active ingredient is also available in different forms, such as injectable solutions, which are specified for administration via injection for specific clinical needs.


Q: Is Maxifol 5000 suitable for individuals under the age of 18?

A: Yes, Folic acid 5 mg (Maxifol 5000) is officially approved for use in the pediatric population, including children over one year old and infants up to one year old. However, infants require a specific lower dose that is calculated based on their weight.


Q: Does Maxifol 5000 cause changes in mood or behavior?

A: Mood alterations or increased irritability have been reported rarely in association with high-dose Folic acid use. If a patient experiences notable or persistent changes in mood, they should report these to their doctor.


Q: Can Maxifol 5000 affect the ability to drive or operate machinery?

A: Official prescribing information states that Maxifol 5000 is not likely to negatively affect the ability to drive or safely use tools or machinery. However, patients should be mindful of rare side effects, such as dizziness, and should take caution if they experience them.


Q: Is Maxifol 5000 the same as its reference listed drug?

A: Maxifol 5000 contains Folic acid 5 mg, which is chemically the same as the active ingredient in the Reference Listed Drug (RLD). The RLD is the original, FDA-approved innovator product used as the standard for all generic medicines of the same type.


Q: Can Maxifol 5000 be safely stopped suddenly?

A: Folic acid is not associated with any known withdrawal symptoms upon sudden cessation. Treatment completion or cessation should always occur under the guidance of a prescribing healthcare professional to ensure the underlying condition is fully corrected.

How should Maxifol 5000 be stored and disposed of?

How to Store and Dispose of Maxifol 5000 (Folic Acid)

The official storage conditions for Maxifol 5000 tablets are strictly defined by regulatory authorities to ensure product stability.

Storage Requirements

Condition Regulatory Requirement
Temperature Do not store above 25^circC or 30^circC, depending on the regional label.
Protection Must be kept in the original package and protected from light and moisture.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Maxifol 5000 must be disposed of according to local regulations. The regulatory guidance instructs that the medicine should not be discarded via wastewater or general household waste to protect the environment. Patients should consult a pharmacist for guidance on proper disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxifol 5000 found in:

A-Z Index: